Bactericidal assays for fluoroquinolones.
Gootz
T D
TD
Department of Immunology and Infectious Diseases, Pfizer, Groton, CT, USA.
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004278:DNA, Superhelical / Q000737:chemistry / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000254:growth & development*; D024841:Fluoroquinolones; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology; D009391:Nephelometry and Turbidimetry; D010957:Plasmids / Q000737:chemistry / Q000378:metabolism; D011786:Quality Control; D059005:Topoisomerase II Inhibitors
D000890:Anti-Infective Agents; D004278:DNA, Superhelical; D024841:Fluoroquinolones; D009287:Naphthyridines; D059005:Topoisomerase II Inhibitors; D002939:Ciprofloxacin; C080163:trovafloxacin; D004250:DNA Topoisomerases, Type II; C061363:sparfloxacin